41340-88-9 Usage
Uses
Used in Pharmaceutical Industry:
PIPERAZIN-1-YL-PIPERIDIN-1-YL-METHANONE is used as a key intermediate in the synthesis of new drugs for the treatment of various conditions, including psychiatric disorders and neurological diseases. Its unique molecular structure, incorporating both piperazine and piperidinyl groups, contributes to its potential as a promising pharmaceutical candidate.
Used in Organic Compounds Synthesis:
PIPERAZIN-1-YL-PIPERIDIN-1-YL-METHANONE serves as a valuable building block in the production of diverse organic compounds, such as agrochemicals, dyes, and fragrances. Its structural features make it a versatile intermediate for the synthesis of a wide range of chemical products.
Used in Medicinal Chemistry Research:
As a multifunctional chemical, PIPERAZIN-1-YL-PIPERIDIN-1-YL-METHANONE holds great potential for utility in the field of medicinal chemistry research. Its unique properties and structural features make it an essential component in the development of innovative pharmaceuticals and organic compounds, driving advancements in the industry.
Check Digit Verification of cas no
The CAS Registry Mumber 41340-88-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 4,1,3,4 and 0 respectively; the second part has 2 digits, 8 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 41340-88:
(7*4)+(6*1)+(5*3)+(4*4)+(3*0)+(2*8)+(1*8)=89
89 % 10 = 9
So 41340-88-9 is a valid CAS Registry Number.
InChI:InChI=1/C10H19N3O/c14-10(12-6-2-1-3-7-12)13-8-4-11-5-9-13/h11H,1-9H2
41340-88-9Relevant academic research and scientific papers
Thienopyrimidine and furan and pyrimidine derivatives, its preparation process and its use in medicine
-
Paragraph 0160-0162, (2016/10/09)
Disclosed are thienopyrimidine and furopyrimidine derivatives, the preparation method thereof and the medical use thereof. The derivatives have a structure as shown in formula V. The thienopyrimidine and furopyrimidine derivatives provided in the present invention have dominant EGFR inhibiting activity, and some of these compounds also have dominant inhibiting activity against VEGFR; therefore, same can expect to be developed as tyrosine kinase EGFR and/or VEGFR inhibitors, and to be used for preparing the drugs for preventing or treating the diseases related to epidermal growth factor receptor EGFR and/or vascular endothelial growth factor receptor VEGFR. Provided is a new development direction and approach for developing novel tyrosine kinase inhibitor drugs having low drug resistance or able to relieve drug resistance to the inhibitor in the early stages, thereby having extensive application prospects and medical value.
Piperazino quinazoline bronchodilators
-
, (2008/06/13)
A series of novel 4-piperazino-6,7-dialkoxyquinazolines and 1-piperazino-6,7-dialkoxyisoquinolines have been prepared, including their acid addition salts. These compounds are useful in therapy as bronchodilators and as smooth muscle relaxants. Methods for their preparation from known compounds are provided.
